Momentum Builds for ALX Oncology and Delta Apparel
- October 03rd, 2023
- 406 views
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 20% in after-hours trading following the announcement that it will unveil interim Phase 2 ASPEN-06 clinical trial results of evorpacept, aimed at treating advanced HER2-positive gastric cancer, on Tuesday, October 3.
$ALXO was trading at $5.90, marking a substantial increase of $1.09 (+22.66%) during the extended session.
In unrelated news, Delta Apparel, Inc. (NYSE American: DLA) revealed that it has received an unsolicited offer for its Salt Life business unit. The company's Board of Directors has enlisted Baird as its financial advisor for this development. It's important to note that the timing, terms, or structure of any potential transaction, as well as the likelihood of a transaction occurring, remain uncertain.
In after-hours, $DLA was trading at $7.89, up $1.30 (+19.73%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login